Perioperative Oral Decontamination and ImmunoNuTrition (POINT) in Elderly (POINT)
Perioperative Oral Decontamination and ImmunoNuTrition (POINT) on Postoperative Pulmonary Complications in Elderly: a Multicenter Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lu Che, Dr
- Phone Number: 69152020
- Email: tracymaobao@126.com
Study Locations
-
-
-
Peking, China
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Lu Che, M.D
- Email: tracymaobao@126.com
-
-
Hebei
-
Shijiazhuang, Hebei, China
- Recruiting
- The Second Hospital of Hebei Medical University
-
Contact:
- Chaolei Liu
- Email: verna521@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age≥65 years;
- undergoing major non-cardiac surgery;
- scheduled for general anesthesia and endotracheal intubation;
- American Society of Anesthesiologists (ASA) physical status classification I-IV;
- with intermediate to high risk of respiratory complications assessed by Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) score;
- informed consent obtained.
Exclusion Criteria:
- emergency surgery;
- preoperative pneumonia;
- allergic to chlorhexidine;
- severe hepatic/renal dysfunction, incapable of oral feeding, with autoimmune diseases, taking immunosuppressant or immunoregulation medications, or with other contraindication to immunonutrition supplementation;
- expected intervention of immunonutrition<3 days.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group A (immunonutrition and oral chlorhexidine decontamination, IN&CD)
Patients in this group will receive immunonutrition supplementation from the day of allocation at the preoperative anesthesia clinic until the day before surgery (usually 1-3 weeks), which is oral intake of ORAL IMPACT™ 2 servings per day.
Patients will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
|
For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.
For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.
|
|
Experimental: Group B (immunonutrition and routine oral care, IN&RC)
Patients in this group will receive immunonutrition supplementation from the day of allocation at the preoperative anesthesia clinic until the day before surgery (usually 1-3 weeks), which is oral intake of ORAL IMPACT™ 2 servings per day.
For oral health care, they will receive routine oral care which is routine toothbrushing twice daily.
|
For intervention group, patients will take immunonutrition supplement after recruitment until the day before surgery.
|
|
Experimental: Group C (routine nutrition advice and oral chlorhexidine decontamination, RN&CD)
Patients in this group will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d.
They will also receive oral chlorhexidine decontamination using 0.12% chlorhexidine oral rinse twice daily from the day before surgery until postoperative day 3.
|
For intervention group, patients will use 0.12% chlorhexidine for oral rinse twice daily from the day before surgery until 3 days after surgery.
|
|
No Intervention: Group D (routine nutrition advice and routine oral care, RN&RC)
Patients in this group will be advised to follow a standard nutrition advice with a total intake of 30kcal/kg/d and protein intake of 1.2g/kg/d.
They will also receive routine oral care which is routine toothbrushing twice daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative pulmonary complications
Time Frame: within 7 days after surgery
|
composite outcome of postoperative pulmonary complications, including pneumonia, atelectasis, pneumothorax, bronchospasm, pleural effusion, hypoxemia, acute respiratory failure, prolonged mechanical ventilation, unplanned re-intubation,etc.
|
within 7 days after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative pneumonia
Time Frame: within 7days and 30 days after surgery
|
defined according to the US Centers for Disease Control Definition
|
within 7days and 30 days after surgery
|
|
postoperative pulmonary complications
Time Frame: within 30 days after surgery
|
composite outcome of postoperative pulmonary complications, including pneumonia, atelectasis, pneumothorax, bronchospasm, pleural effusion, hypoxemia, acute respiratory failure, prolonged mechanical ventilation, unplanned re-intubation,etc.
|
within 30 days after surgery
|
|
postoperative infectious complications
Time Frame: within 7days and 30 days after surgery
|
composite outcome including surgical site infection, respiratory infection, urinary tract infection, intra-abdominal infection, blood stream infection, etc.
|
within 7days and 30 days after surgery
|
|
postoperative complications
Time Frame: within 7days and 30 days after surgery
|
defined using comprehensive complication index
|
within 7days and 30 days after surgery
|
|
postoperative recovery
Time Frame: within 7days and 30 days after surgery
|
assessed by 15-item quality of recovery questionnaire and WHO disability assessment schedule 2.0
|
within 7days and 30 days after surgery
|
|
hospitalization expenses
Time Frame: upon hospital discharge, typically 1-2 weeks
|
total expense during the hospital stay
|
upon hospital discharge, typically 1-2 weeks
|
|
length of hospital stay
Time Frame: upon hospital discharge,typically 1-2 weeks
|
days of in hospital stay
|
upon hospital discharge,typically 1-2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Yuguang Huang, Dr, Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- I-23PJ953
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.